GlassScriptPhysician profile
James S Kong
NPI 1366426470
$16,005.80
in general payments reported to CMS, 2019-2025
46 companies · $3,371 in 2025
The $3,371 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $1,592 · 2021: $2,191 · 2022: $2,146 · 2023: $2,406 · 2024: $2,091 · 2025: $3,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,805 · Education: $63.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,804.68 |
| Education | $63.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,868.09 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,942.22 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,630.54 | 2019-2025 | Nucala, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $1,286.45 | 2019-2022 | |
| Novo Nordisk INC | $1,225.77 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $999.02 | 2019-2025 | |
| Genzyme Corporation | $828.97 | 2019-2025 | |
| Lilly USA, LLC | $480.75 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Greer Laboratories, INC. | $410.88 | 2019-2025 | Oralair |
| Regeneron Healthcare Solutions, INC. | $408.31 | 2021-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $369.10 | 2019-2025 | Capvaxive, Gardasil 9, Proquad |
| Arbor Pharmaceuticals, INC. | $318.30 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $295.05 | 2023-2025 | Contrave, Onzetra Xsail, Nexletol |
| Organon LLC | $253.79 | 2025 | Vtama |
| Amgen INC. | $215.01 | 2023-2025 | Tezspire, Repatha, Otezla |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.